Table 1 Patient characteristics in 106 patients with newly diagnosed metastatic posterior uveal melanoma.

From: 18F-FDG PET/CT assessment of metabolic tumor burden predicts survival in patients with metastatic posterior uveal melanoma

Sex, n

Women

59 (56%)

Men

47 (44%)

Age at metastatic diagnosis

Median

65 (IQR 59–73)

< 60 years of age, n

28 (26%)

≥ 60 years of age, n

78 (74%)

Time from primary diagnosis to first metastasis (months), median (IQR)

27.0 (12.0–44.0)

Time from date of metastatic diagnosis until PET/CT (days), median (IQR)

9.5 (6.0–15.0)

Overall survival (months), median (IQR)

11.5 (7.0–20.0)

18F-FDG PET parametera, median

SUVmax

10.1 (IQR 6.5–15.4)

MTV (cm3)

14.6 (IQR 3.0-88.6)

TLG

85.5 (IQR 16.5-570.5)

Liver-SUVmax

8.9 (IQR 5.8–13.2)

Liver-MTV (cm3)

13.8 (IQR 1.19–62.5)

Liver-TLG

73.6 (IQR 5.5-387.8)

LDLM (mm), median (IQR)b

30 (19.0–52.0)

AJCC stage IV, n

M1a

54 (51%)

M1b

40 (38%)

M1c

12 (11%)

Metastatic pattern, n

Hepatic pattern

62 (58%)

Hepatic-extrahepatic pattern

35 (33%)

Extrahepatic pattern

9 (8%)

WHO/ECOG performance status, n

0–1

84 (79%)

2–4

9 (9%)

Missing values

13 (12%)

First-line ipi + nivo treatmentc, n

No

73 (69%)

Yes

33 (31%)

Resection of metastatic lesion(s), n

No

90 (85%)

Yes

16 (15%)

  1. 18F-FDG = 18F-fludeoxyglucose; AJCC = American Joint Committee on Cancer; AP = alkaline phosphatase; ECOG = Eastern Cooperative Oncology Group; ipi + nivo = ipilimumab and nivolumab; IQR = interquartile range; LDH = lactase dehydrogenase; LDLM = largest diameter of the largest metastatic lesions; MBq = megaBecquerel; MTV = metabolic tumor volume; SUV = Maximum Standardized Uptake Value; TLG = tumor lesion glycolysis; UNL = upper normal limit; WHO = World Health Organization.
  2. aSUV threshold = 4.0.
  3. bLargest diameter of the largest metastatic lesion in any organ.
  4. cFirst-line treatment with the combination of ipilimumab and nivolumab.
Back to article page